68Ga-FAPI与18F-FDG PET/CT在胆道癌肿瘤分期中的前瞻性比较
单中心前瞻性研究纳入18例原发性或复发性胆道癌患者,比较68Ga-FAPI与18F-FDG PET/CT对原发灶、淋巴结转移和远处转移的检出效能。68Ga-FAPI PET/CT对原发灶(16/16 vs 13/16)、淋巴结转移(41/42 vs 35/42)和远处转移(99/99 vs 78/99)的敏感度均高于18F-FDG PET/CT,并在10/18例中提供新的肿瘤学发现、5/18例中上调肿瘤分期或再分期。
要点
- 68Ga-FAPI PET/CT对胆道癌原发灶、淋巴结转移和远处转移的敏感度均高于18F-FDG PET/CT。
- 68Ga-FAPI PET/CT在10/18例中提供新的肿瘤学发现,在5/18例中上调分期或再分期。
- 68Ga-FAPI在炎性病变中的平均SUVmax低于肿瘤性病变(4.9±2.6 vs 10.0±4.6,P=.003)。
核心结论
- 68Ga-FAPI PET/CT用于肿瘤分期在胆道癌中显示出更准确分期的潜力,从而可能改善治疗决策。
研究设计与样本
- 单中心前瞻性临床研究,2020年6月至2021年6月在西南医科大学附属医院开展,纳入18例原发性或复发性胆道癌患者(平均年龄61岁±10[SD]),所有患者均接受68Ga-FAPI和18F-FDG PET/CT检查,以组织病理学检查、形态学影像和/或随访影像为参考标准。
诊断标准与关键数值
- 68Ga-FAPI PET/CT检出原发灶的敏感度为16/16(100%),18F-FDG PET/CT为13/16(81%)。
- 68Ga-FAPI PET/CT检出淋巴结转移的敏感度为41/42(98%),18F-FDG PET/CT为35/42(83%)。
- 68Ga-FAPI PET/CT检出远处转移的敏感度为99/99(100%),18F-FDG PET/CT为78/99(79%)。
- 68Ga-FAPI PET/CT在肿瘤相关梗阻所致炎性过程中的敏感度为7/8(88%),18F-FDG PET/CT为1/8(13%)。
- 68Ga-FAPI在炎性病变中的平均SUVmax为4.9±2.6,低于肿瘤性病变的10.0±4.6(P=.003)。
临床应用与阅片要点
- 68Ga-FAPI PET/CT较18F-FDG PET/CT在10/18例中提供新的肿瘤学发现。
- 68Ga-FAPI PET/CT较18F-FDG PET/CT在5/18例中上调肿瘤分期或再分期。
- 68Ga-FAPI在肿瘤相关梗阻所致炎性过程中亦可摄取,阅片时需结合病变部位与SUVmax(炎性病变平均4.9±2.6 vs 肿瘤性病变10.0±4.6)进行鉴别。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Gallium 68-labeled fibroblast-activation protein inhibitor (68Ga-FAPI), an imaging agent for detecting tumors, represents a promising alternative to fluorine 18 fluorodeoxyglucose (18F-FDG). Purpose To compare the potential efficacy of 68Ga-FAPI PET/CT with that of 18F-FDG PET/CT for detecting primary tumor and nodal and distant metastases in biliary tract cancer (BTC) and to explore the impact (tumor staging) of 68Ga-FAPI compared with 18F-FDG on clinical management of BTC. Materials and Methods This single-center prospective clinical study was performed at the Affiliated Hospital of Southwest Medical University between June 2020 and June 2021. Participants with BTC underwent both 68Ga-FAPI and 18F-FDG PET/CT. Histopathologic examination, morphologic imaging, and/or follow-up imaging served as the reference standard. The maximum standardized uptake value (SUVmax) of the primary tumor and nodal and distant metastases between 18F-FDG and 68Ga-FAPI PET/CT were compared using the paired-sample t test. Results Eighteen participants with primary or recurrent BTC were evaluated (mean age, 61 years ± 10 [SD]). The sensitivity of 68Ga-FAPI PET/CT was higher than that of 18F-FDG PET/CT for detecting primary tumors (16 of 16 [100%] vs 13 of 16 [81%]), nodal metastases (41 of 42 [98%] vs 35 of 42 [83%]), and distant metastases (99 of 99 [100%] vs 78 of 99 [79%]). 68Ga-FAPI PET/CT resulted in new oncologic findings in 10 of 18 participants and upgraded tumor staging or restaging in five of 18 participants compared with 18F-FDG PET/CT. 68Ga-FAPI PET/CT demonstrated higher sensitivity than 18F-FDG PET/CT in inflammatory processes secondary to tumor-related obstruction (seven of eight [88%] vs one of eight [13%]). 68Ga-FAPI showed lower average SUVmax in inflammatory processes than in oncologic lesions (4.9 ± 2.6 vs 10.0 ± 4.6, respectively; P = .003). Conclusion Gallium 68-labeled fibroblast-activation protein inhibitor PET/CT for tumor staging showed potential for more accurate staging of biliary tract cancer, thereby improving treatment decision making. Clinical trial registration no. ChiCTR2100044131 © RSNA, 2022 Online supplemental material is available for this article. See also the editorial by Choyke in this issue.
引用
- Lan, Zhang, Xu, et al. Prospective Comparison of 68Ga-FAPI versus 18F-FDG PET/CT for Tumor Staging in Biliary Tract Cancers. Radiology. 2022. PMID: 35579524. doi:10.1148/radiol.213118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。